,Term,Overlap,Adjusted P-value,Genes
1,Senescence and autophagy,13/99,1.34e-12,JUN; CDKN1A; CXCL8; SERPINB2; CDKN2A; SERPINE1; IL24; MAPK14; THBS1; GABARAP; IFNG; IFI16; CCL3
2,Interleukin-2 signaling pathway,24/847,8.49e-10,CX3CR1; FCGBP; JUN; CXCL8; SERPINE1; IL24; ARAP2; NKG7; FURIN; KIR2DL1; MAPK14; PRSS23; NELL2; LDHB; ABLIM1; IFNG; PLAU; PPP2R2B; CCL3; FLNB; JAK3; LDLR; GBP1; BIRC3
3,Gastrin pathway,7/44,3.91e-07,JUN; CXCL8; SERPINB2; CDKN2A; SERPINE1; HBEGF; BIRC3
4,T cell receptor regulation of apoptosis,16/603,5.75e-06,EGR1; JUN; CDKN1A; CXCL8; SERPINE2; CDKN2A; RHOC; MAPK14; CLK1; PNP; IFNG; IFI16; CCL3; MYBL2; GBP1; BIRC3
5,Chagas disease,8/104,5.75e-06,JUN; CXCL8; IFNG; PPP2R2B; CCL3L3; SERPINE1; CCL3; MAPK14
6,EGFR1 pathway,9/152,6.62e-06,CLK1; SELENBP1; CDKN1A; PNP; MME; PLAU; IGFBP3; MYBL2; HBEGF
7,p53 activity regulation,8/118,1.10e-05,CDKN1A; CDKN2A; IGFBP3; SERPINE1; SESN2; SIAH1; MAPK14; THBS1
8,AP-1 transcription factor network,6/70,9.58e-05,EGR1; JUN; CXCL8; IFNG; PLAU; CDKN2A
9,Bladder cancer,5/42,1.17e-04,CDKN1A; CXCL8; CDKN2A; DAPK2; THBS1
10,E2F transcription factor network,6/74,1.17e-04,CDKN1A; PLAU; CDKN2A; SERPINE1; MYBL2; WASF1
11,ID regulation of gene expression,4/20,1.37e-04,CDKN1A; CXCL8; CDKN2A; THBS1
12,Regular glucocorticoid receptor pathway,6/82,1.63e-04,EGR1; CDKN1A; JUN; CXCL8; IFNG; MAPK14
13,TSP1-induced apoptosis in microvascular endothelial cell,3/8,2.69e-04,JUN; MAPK14; THBS1
14,Dissolution of fibrin clot,3/8,2.69e-04,SERPINB2; PLAU; SERPINE1
15,Fibroblast growth factor 1,4/26,3.01e-04,CDKN1A; SERPINB2; PLAU; SERPINE1
16,Immune system,17/998,3.01e-04,EGR1; JUN; CDKN1A; GBP7; UBE2L6; KIR2DL1; MAPK14; KIR2DL3; KIR2DL4; AIM2; IFNG; FLNB; TLR5; FCGR1A; JAK3; GBP1; BIRC3
17,ATF2 transcription factor network,5/59,3.79e-04,JUN; CXCL8; IFNG; PLAU; MAPK14
18,CD40/CD40L signaling,4/31,5.23e-04,JUN; MAPK14; JAK3; BIRC3
19,HIF-1 transcriptional activity in hypoxia,5/66,5.89e-04,NT5E; JUN; SERPINE1; SLC2A1; FURIN
20,Interferon signaling,7/168,6.10e-04,EGR1; GBP7; IFNG; UBE2L6; FLNB; FCGR1A; GBP1
21,Oncostatin M,9/311,7.01e-04,SELENBP1; JUN; CDKN1A; CXCL8; SERPINB2; PLAU; SERPINE1; LDLR; TGM2
22,Interleukin-1 regulation of extracellular matrix,6/120,7.94e-04,JUN; CXCL8; SERPINB2; IFNG; BIRC3; HBEGF
23,FRA pathway,4/37,8.39e-04,JUN; CXCL8; PLAU; CDKN2A
24,Pathways in cancer,9/325,8.65e-04,JUN; CDKN1A; CDKN2B; CXCL8; FLT3; CDKN2A; DAPK2; SLC2A1; BIRC3
25,Antigen processing and presentation,5/81,1.08e-03,IFNG; KIR2DL1; KIR2DL3; KIR2DL4; HSPA1B
26,Fibrinolysis pathway,3/15,1.08e-03,SERPINB2; PLAU; SERPINE1
27,BDNF signaling pathway,8/261,1.08e-03,EGR1; CHRNA3; JUN; CDKN1A; ABLIM1; IGFBP3; SERPINE1; HSPA1B
28,FSH regulation of apoptosis,8/263,1.08e-03,CX3CR1; ABLIM1; IGFBP3; APOE; MAPK14; THBS1; LDLR; GBP1
29,Interleukin-4 regulation of apoptosis,8/267,1.14e-03,SLC22A4; JUN; CDKN1A; CXCL8; LRRN3; IFI16; NKG7; UBE2L6
30,Chylomicron-mediated lipid transport,3/17,1.47e-03,APOE; LDLRAP1; LDLR
31,"Immune system signaling by interferons, interleukins, prolactin, and growth hormones",8/280,1.49e-03,EGR1; GBP7; IFNG; UBE2L6; FLNB; FCGR1A; JAK3; GBP1
32,Interleukin-5 regulation of apoptosis,6/144,1.51e-03,EGR1; CXCL8; CCL3; MAPK14; BIRC3; HBEGF
33,Regulation of NFAT transcription factors,4/47,1.52e-03,EGR1; JUN; CXCL8; IFNG
34,Wnt signaling pathway and pluripotency,5/98,2.02e-03,JUN; PLAU; PPP2R2B; PRKCZ; LDLR
35,Vitamin B12 metabolism,4/52,2.02e-03,IFNG; SERPINE1; APOE; LDLR
36,4-1BB-dependent immune response,3/20,2.02e-03,JUN; IFNG; MAPK14
37,TSH regulation of gene expression,5/97,2.02e-03,EGR1; JUN; DUSP2; CXCL8; LRRN3
38,Pyrimidine metabolism,5/100,2.17e-03,NT5E; PNP; POLR1D; CMPK2; DCK
39,Wnt signaling pathway,7/231,2.33e-03,JUN; PLAU; PPP2R2B; SIAH1; KREMEN1; PRKCZ; LDLR
40,TAp63 pathway,4/55,2.33e-03,CDKN1A; CDKN2A; IGFBP3; MFGE8
41,Blood clotting cascade,3/23,2.62e-03,SERPINB2; PLAU; SERPINE1
42,Signaling events mediated by PRL,3/23,2.62e-03,EGR1; CDKN1A; RHOC
43,Cyclins and cell cycle regulation,3/23,2.62e-03,CDKN1A; CDKN2B; CDKN2A
44,RAGE pathway,4/60,2.97e-03,CXCL8; SERPINE1; MFGE8; LDLR
45,Epidermal growth factor receptor (EGFR) pathway,5/111,2.98e-03,JUN; CDKN2A; RHOC; MAPK14; PRKCZ
46,Folate metabolism,4/63,3.43e-03,IFNG; SERPINE1; FOLR3; LDLR
47,TWEAK regulation of gene expression,3/27,3.78e-03,CXCL8; SERPINE1; CCL3
48,Retinoblastoma protein regulation,4/66,3.78e-03,CDKN1A; JUN; CDKN2A; MAPK14
49,Signaling by TGF-beta receptor complex,4/66,3.78e-03,CDKN2B; SERPINE1; FURIN; PRKCZ
50,TGF-beta signaling pathway,6/185,3.78e-03,TGFBR3; JUN; IFNG; SERPINE1; MAPK14; THBS1
51,Chemokine signaling pathway,6/189,3.92e-03,CX3CR1; CXCL8; CCL3L3; CCL3; PRKCZ; JAK3
52,Epithelial cell signaling in Helicobacter pylori infection,4/68,3.92e-03,JUN; CXCL8; MAPK14; HBEGF
53,Cell cycle: G1/S checkpoint,3/28,3.92e-03,CDKN1A; CDKN2B; CDKN2A
54,Cytokine-cytokine receptor interaction,7/265,3.92e-03,CX3CR1; CXCL8; IFNG; FLT3; CCL3L3; IL24; CCL3
55,Lipoprotein metabolism,3/29,4.13e-03,APOE; LDLRAP1; LDLR
56,Interleukin-1 signaling pathway,5/125,4.15e-03,JUN; CXCL8; UBE2L6; MAPK14; PRKCZ
57,Leishmaniasis,4/72,4.62e-03,JUN; IFNG; FCGR1A; MAPK14
58,Endocytosis,6/201,5.06e-03,ARAP2; FOLR3; LDLRAP1; PRKCZ; LDLR; HSPA1B
59,Interleukin-7 interactions in immune response,3/34,6.20e-03,JUN; CXCL8; IL24
60,p53 signaling pathway,5/139,6.29e-03,JUN; CDKN1A; IGFBP3; SERPINE1; HSPA1B
61,EGF/EGFR signaling pathway,5/141,6.60e-03,ATXN2; JUN; MYBL2; MAPK14; PRKCZ
62,Toll-like receptor signaling pathway regulation,5/142,6.70e-03,JUN; CXCL8; CCL3; TLR5; MAPK14
63,ATM-dependent DNA damage response,4/82,6.73e-03,CDKN1A; JUN; PLAU; LDLR
64,SMAD2/3 nuclear pathway,4/82,6.73e-03,CDKN1A; JUN; CDKN2B; SERPINE1
65,MAP kinase pathway regulation through dual specificity phosphatases,2/9,7.47e-03,DUSP2; MAPK14
66,NOD signaling pathway,4/85,7.47e-03,CXCL8; AIM2; MAPK14; BIRC3
67,Cyclin D-associated events in G1,3/38,7.59e-03,CDKN1A; CDKN2B; CDKN2A
68,Purine catabolism,2/10,8.87e-03,NT5E; PNP
69,Activation of the AP-1 family of transcription factors,2/10,8.87e-03,JUN; MAPK14
70,Graft-versus-host disease,3/41,9.07e-03,IFNG; KIR2DL1; KIR2DL3
71,Netrin-1 signaling,3/42,9.60e-03,ABLIM1; SIAH2; SIAH1
72,Interferon-gamma signaling pathway,4/97,1.12e-02,GBP7; IFNG; FCGR1A; GBP1
73,Interleukin-12/STAT4 pathway,3/45,1.14e-02,JUN; IFNG; MAPK14
74,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",3/47,1.28e-02,AIM2; MAPK14; BIRC3
75,"Lipid digestion, mobilization, and transport",3/48,1.34e-02,APOE; LDLRAP1; LDLR
76,Purine salvage,2/13,1.38e-02,PNP; DCK
77,TGF-beta regulation of extracellular matrix,9/565,1.53e-02,CLK1; TGFBR3; SELENBP1; CDKN2B; MME; CDKN2A; SERPINE1; SLC2A1; APOE
78,Malaria,3/51,1.53e-02,CXCL8; IFNG; THBS1
79,Platelet amyloid precursor protein pathway,2/14,1.55e-02,PLAU; SERPINE1
80,Androgen receptor regulation of biosynthesis and transcription,3/53,1.67e-02,EGR1; JUN; MAPK14
81,Adhesion and diapedesis of granulocytes,2/15,1.70e-02,CXCL8; IFNG
82,Erythrocyte differentiation pathway,2/15,1.70e-02,FLT3; CCL3
83,Binding of chemokines to chemokine receptors,3/54,1.70e-02,CX3CR1; CXCL8; CCL3
84,Fas signaling pathway,4/115,1.78e-02,CXCL8; MAPK14; PRKCZ; BIRC3
85,Insulin signaling pathway,6/277,1.78e-02,EGR1; JUN; SLC2A1; RHOC; MAPK14; PRKCZ
86,Thromboxane A2 receptor signaling,3/56,1.82e-02,MAPK14; PRKCZ; TGM2
87,Selenium metabolism and selenoproteins,2/16,1.84e-02,SELENBP1; JUN
88,Prolactin regulation of apoptosis,4/118,1.85e-02,LDHB; EGR1; GBP1; BACH2
89,Keratinocyte differentiation,3/57,1.85e-02,JUN; MAPK14; BIRC3
90,Selenium pathway,3/60,2.12e-02,IFNG; SERPINE1; LDLR
91,p75 neurotrophin receptor-mediated signaling,4/124,2.16e-02,FURIN; RHOC; PRKCZ; BIRC3
92,FGF signaling pathway,3/61,2.17e-02,JUN; PLAU; MAPK14
93,Pertussis toxin-insensitive CCR5 signaling in macrophage,2/18,2.18e-02,JUN; MAPK14
94,Shigellosis,3/62,2.22e-02,CXCL8; WASF1; MAPK14
95,TP53 network,2/19,2.35e-02,CDKN1A; CDKN2A
96,Tob role in T-cell activation,2/19,2.35e-02,TGFBR3; IFNG
97,Angiotensin II-stimulated signaling through G-proteins and beta-arrestin,3/64,2.36e-02,EGR1; MAPK14; PRKCZ
98,Interleukin-12-mediated signaling events,3/65,2.41e-02,IFNG; CCL3; MAPK14
99,LPA receptor mediated events,3/65,2.41e-02,JUN; CXCL8; HBEGF
100,Beta-1 integrin cell surface interactions,3/66,2.45e-02,PLAU; THBS1; TGM2
101,Estrogen receptor signaling pathway,2/20,2.45e-02,JUN; MAPK14
102,Hypertrophy pathway,2/20,2.45e-02,IFNG; HBEGF
103,G1 to S cell cycle control,3/67,2.52e-02,CDKN1A; CDKN2B; CDKN2A
104,Mitotic G1-G1/S phases,4/135,2.56e-02,CDKN1A; CDKN2B; CDKN2A; MYBL2
105,CD8/T cell receptor downstream pathway,3/68,2.58e-02,EGR1; JUN; IFNG
106,Natural killer cell-mediated cytotoxicity,4/137,2.60e-02,IFNG; KIR2DL1; KIR2DL3; KIR2DL4
107,Oxidative stress-induced gene expression via Nrf2,2/21,2.60e-02,JUN; MAPK14
108,MAPK signaling pathway,6/314,2.60e-02,JUN; DUSP2; FLNB; MAPK14; PRKCZ; HSPA1B
109,Developmental biology,7/420,2.64e-02,ABLIM1; SIAH2; SIAH1; FURIN; ANGPTL4; RHOC; MAPK14
110,CDC42 signaling events,3/70,2.64e-02,JUN; MAPK14; PRKCZ
111,Nucleotide metabolism,3/70,2.64e-02,NT5E; PNP; DCK
112,T cell receptor signaling pathway,4/139,2.64e-02,JUN; IFNG; ARAP2; MAPK14
113,Innate immune system,6/319,2.64e-02,JUN; AIM2; UBE2L6; TLR5; MAPK14; BIRC3
114,Rac1 cell motility signaling pathway,3/71,2.64e-02,JUN; WASF1; MAPK14
115,Interleukin-6 signaling pathway,3/71,2.64e-02,JUN; MAPK14; JAK3
116,Mitochondrial pathway of apoptosis: multidomain Bcl-2 family,3/71,2.64e-02,DAPK2; PRKCZ; HSPA1B
117,Hypoxia and p53 in the cardiovascular system,2/23,2.82e-02,CDKN1A; IGFBP3
118,RANKL regulation of apoptosis and immune response,3/74,2.91e-02,EGR1; JUN; CCL3
119,Tumor suppressor Arf inhibits ribosomal biogenesis,2/24,2.99e-02,CDKN2A; POLR1D
120,Nicotinate and nicotinamide metabolism,2/24,2.99e-02,NT5E; PNP
121,IGF1 receptor signaling through beta-arrestin,2/25,3.21e-02,PPP2R2B; MAPK14
122,Apoptosis regulation,3/78,3.25e-02,CDKN1A; IFNG; DAPK2
123,p73 transcription factor network,3/79,3.31e-02,CDKN1A; SERPINE1; MAPK14
124,Signaling events mediated by hepatocyte growth factor receptor (c-Met),3/79,3.31e-02,EGR1; JUN; PRKCZ
125,Physiological and pathological hypertrophy  of the heart,2/26,3.32e-02,JUN; MAPK14
126,Selective expression of chemokine receptors during T-cell polarization,2/26,3.32e-02,IFNG; CCL3
127,Apoptosis modulation and signaling,3/80,3.32e-02,JUN; CDKN2A; BIRC3
128,Nuclear beta-catenin signaling and target gene transcription regulation,3/80,3.32e-02,JUN; CXCL8; CDKN2A
129,Integrin signaling pathway,4/155,3.35e-02,JUN; CDKN2A; RHOC; MAPK14
130,CTCF pathway,2/27,3.45e-02,TGFBR3; CDKN2A
131,TNF/stress-related signaling,2/27,3.45e-02,JUN; MAPK14
132,Toll receptor cascades,4/159,3.57e-02,JUN; UBE2L6; TLR5; MAPK14
133,Differentiation pathway in PC12 cells,3/84,3.66e-02,EGR1; JUN; MAPK14
134,C-Myb transcription factor network,3/85,3.72e-02,CDKN1A; CDKN2A; BIRC3
135,TGF-beta regulation of skeletal system development,3/85,3.72e-02,CDKN2B; IFNG; THBS1
136,Hemostasis pathway,7/468,3.76e-02,SERPINB2; PLAU; SIRPG; SERPINE1; MAPK14; PRKCZ; THBS1
137,Statin pathway,2/29,3.76e-02,APOE; LDLR
138,T cell receptor calcium pathway,2/29,3.76e-02,JUN; IFNG
139,Purine metabolism,4/164,3.77e-02,NT5E; PNP; POLR1D; DCK
140,Inflammatory response pathway,2/30,3.85e-02,IFNG; THBS1
141,Tumor necrosis factor (TNF) pathway,2/30,3.85e-02,JUN; BIRC3
142,Nuclear events mediated by MAP kinases,2/30,3.85e-02,JUN; MAPK14
143,Hematopoietic cell lineage,3/88,3.85e-02,MME; FLT3; FCGR1A
144,TNFR1 signaling pathway,2/30,3.85e-02,JUN; BIRC3
145,Alpha-V beta-3 integrin/OPN pathway,2/31,4.05e-02,JUN; PLAU
146,NF-kappaB activation by non-typeable Hemophilus influenzae,2/31,4.05e-02,CXCL8; MAPK14
147,ERBB signaling pathway,3/94,4.49e-02,CDKN1A; JUN; HBEGF
148,HIF-2-alpha transcription factor network,2/34,4.74e-02,SERPINE1; SLC2A1
149,MAPK/TRK pathway,2/34,4.74e-02,EGR1; MAPK14
150,Mitochondrial pathway of apoptosis: BH3-only Bcl-2 family,3/97,4.79e-02,JUN; PPP2R2B; PRKCZ
151,Autophagy regulation,2/35,4.88e-02,IFNG; GABARAP
152,Cytokines and inflammatory response,2/35,4.88e-02,CXCL8; IFNG
153,Interleukin-2/PI3K pathway,2/35,4.88e-02,PRKCZ; JAK3
154,TNF-alpha signaling pathway,3/101,5.16e-02,JUN; PRKCZ; BIRC3
155,GnRH signaling pathway,3/101,5.16e-02,JUN; MAPK14; HBEGF
156,Interleukin-23-mediated signaling events,2/37,5.32e-02,IFNG; IL24
157,Signal transduction through IL-1R,2/38,5.53e-02,JUN; MAPK14
158,p38 alpha/beta MAPK downstream pathway,2/38,5.53e-02,JUN; MAPK14
159,Amoebiasis,3/105,5.55e-02,CXCL8; SERPINB2; IFNG
160,Fibroblast growth factor receptor pathway,3/105,5.55e-02,CDKN2A; MAPK14; PRKCZ
161,ERBB1 downstream pathway,3/106,5.65e-02,EGR1; JUN; PRKCZ
162,Angiotensin II-mediated activation of JNK pathway via Pyk2-dependent signaling,2/39,5.66e-02,JUN; MAPK14
163,G alpha i pathway,3/108,5.87e-02,MAPK14; PRKCZ; HBEGF
164,Jak-STAT signaling pathway,4/199,6.04e-02,CXCL8; IFNG; IL24; JAK3
165,Alpha-M beta-2 integrin signaling,2/41,6.04e-02,PLAU; PRKCZ
166,Transcriptional activity of SMAD2/SMAD3-SMAD4 heterotrimer,2/41,6.04e-02,CDKN2B; SERPINE1
167,FOXM1 transcription factor network,2/41,6.04e-02,CDKN2A; HSPA1B
168,TWEAK signaling pathway,2/42,6.25e-02,JUN; MAPK14
169,Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling,2/42,6.25e-02,PLAU; SERPINE1
170,Beta-3 integrin cell surface interactions,2/43,6.46e-02,PLAU; THBS1
171,"Platelet activation, signaling and aggregation",4/205,6.46e-02,SERPINE1; MAPK14; PRKCZ; THBS1
172,PI3K events in ERBB2 signaling,2/44,6.70e-02,CDKN1A; HBEGF
173,RhoA signaling pathway,2/45,6.87e-02,JUN; PRKCZ
174,Wnt interactions in lipid metabolism and immune response,2/45,6.87e-02,SIAH2; APOE
175,Interleukin-3 signaling pathway,2/45,6.87e-02,JUN; CXCL8
176,Immunoregulatory interactions between a lymphoid and a non-lymphoid cell,3/119,7.01e-02,KIR2DL1; KIR2DL3; KIR2DL4
177,Notch signaling pathway,3/121,7.28e-02,CDKN1A; FURIN; BIRC3
178,Delta Np63 pathway,2/47,7.33e-02,CDKN2A; IGFBP3
179,Signaling by PDGF,3/122,7.35e-02,CDKN1A; FURIN; THBS1
180,ATM pathway,2/48,7.54e-02,CDKN1A; JUN
181,Phospholipase C delta-1 interactions in phospholipid-associated cell signaling,1/5,7.58e-02,TGM2
182,Kit receptor transcriptional targets,1/5,7.58e-02,SLC2A1
183,Maturation of Notch precursor via proteolytic cleavage,1/5,7.58e-02,FURIN
184,Angiopoietin receptor Tie2-mediated signaling,2/49,7.58e-02,CDKN1A; MAPK14
185,Ceramide signaling pathway,2/49,7.58e-02,PRKCZ; BIRC3
186,G alpha 12 pathway,2/49,7.58e-02,JUN; MAPK14
187,Type II interferon signaling (interferon-gamma),2/50,7.83e-02,IFNG; GBP1
188,PI3K pathway,2/53,8.67e-02,CDKN2A; PRKCZ
189,Focal adhesion,4/233,8.70e-02,JUN; FLNB; THBS1; BIRC3
190,ADP signalling through P2Y purinoceptor 1,1/6,8.70e-02,MAPK14
191,Proteolysis and signaling pathway of Notch,1/6,8.70e-02,FURIN
192,Low-density lipoprotein (LDL) pathway during atherogenesis,1/6,8.70e-02,LDLR
193,RANKL signaling pathway,2/54,8.75e-02,JUN; MAPK14
194,"TNF-alpha effects on cytokine activity, cell motility, and apoptosis",3/135,8.80e-02,CXCL8; BIRC3; HBEGF
195,Calcineurin-dependent NFAT signaling role in lymphocytes,2/55,8.91e-02,MAPK14; PRKCZ
196,Ubiquitin-mediated proteolysis,3/136,8.91e-02,SIAH1; UBE2L6; BIRC3
197,Signal transduction,10/1020,8.97e-02,CX3CR1; JUN; CDKN1A; CDKN2B; CXCL8; ARAP2; CCL3; FURIN; MAPK14; HBEGF
198,Cytosolic DNA-sensing pathway,2/56,9.11e-02,AIM2; POLR1D
199,Pre-NOTCH expression and processing,2/57,9.32e-02,JUN; FURIN
200,SHP2 signaling,2/57,9.32e-02,IFNG; JAK3
201,Apoptosis,4/242,9.34e-02,JUN; CDKN2A; DAPK2; BIRC3
202,Highly sodium permeable acetylcholine nicotinic receptors,1/7,9.49e-02,CHRNA3
203,FXR and LXR regulation of cholesterol metabolism,1/7,9.49e-02,LDLR
204,Arachidonate epoxygenase/epoxide hydrolase pathway,1/7,9.49e-02,EPHX2
205,SARS coronavirus protease,1/7,9.49e-02,MAPK14
206,Proepithelin conversion to epithelin and wound repair control,1/8,1.06e-01,CXCL8
207,SREBP control of lipid biosynthesis,1/8,1.06e-01,LDLR
208,Vitamin C (ascorbate) metabolism,1/8,1.06e-01,SLC2A1
209,Organic cation transport,1/8,1.06e-01,SLC22A4
210,Endothelins,2/64,1.10e-01,JUN; MAPK14
211,Glioma,2/65,1.12e-01,CDKN1A; CDKN2A
212,Myometrial relaxation and contraction pathways,3/155,1.14e-01,JUN; IGFBP3; PRKCZ
213,Thyroid-stimulating hormone signaling pathway,2/66,1.14e-01,JUN; MAPK14
214,EGFR transactivation by gastrin,1/9,1.15e-01,HBEGF
215,Rapid glucocorticoid receptor pathway,1/9,1.15e-01,MAPK14
216,Pyrimidine salvage reactions,1/9,1.15e-01,DCK
217,Telomerase regulation,2/67,1.15e-01,JUN; IFNG
218,NFAT involvement in hypertrophy of the heart,2/69,1.21e-01,MAPK14; HBEGF
219,Antiviral mechanism by interferon-stimulated genes,2/70,1.22e-01,UBE2L6; FLNB
220,Renal cell carcinoma,2/70,1.22e-01,JUN; SLC2A1
221,Complement and coagulation cascades,2/70,1.22e-01,PLAU; SERPINE1
222,DCC role in regulating apoptosis,1/10,1.23e-01,DAPK2
223,Free radical-induced apoptosis,1/10,1.23e-01,CXCL8
224,RIG-I-like receptor signaling pathway,2/71,1.23e-01,CXCL8; MAPK14
225,Melanoma,2/71,1.23e-01,CDKN1A; CDKN2A
226,Chronic myeloid leukemia,2/73,1.29e-01,CDKN1A; CDKN2A
227,Myc repressed pathway,2/73,1.29e-01,CDKN1A; CDKN2B
228,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",1/11,1.29e-01,FURIN
229,Osteopontin signaling,1/11,1.29e-01,PLAU
230,Glypican-3 pathway,1/11,1.29e-01,FURIN
231,Erythropoietin-mediated neuroprotection through NF-kB,1/11,1.29e-01,CDKN1A
232,Down syndrome cell adhesion molecule (DSCAM) interactions,1/11,1.29e-01,MAPK14
233,Seven transmembrane receptor signaling through beta-arrestin,2/74,1.29e-01,PPP2R2B; MAPK14
234,Vitamin C in the brain,1/11,1.29e-01,SLC2A1
235,Prolactin activation of MAPK signaling,2/75,1.30e-01,JUN; MAPK14
236,Glycolysis and gluconeogenesis,2/75,1.30e-01,LDHB; SLC2A1
237,Gamma-aminobutyric acid receptor life cycle,1/12,1.35e-01,GABARAP
238,Mitochondrial pathway of apoptosis: caspases,2/77,1.35e-01,HSPA1B; BIRC3
239,Parkin role in the ubiquitin-proteasomal pathway,1/12,1.35e-01,UBE2L6
240,Pyrimidine catabolism,1/12,1.35e-01,NT5E
241,SODD/TNFR1 signaling pathway,1/12,1.35e-01,BIRC3
242,Salmonella infection,1/12,1.35e-01,WASF1
243,D4-GDI signaling pathway,1/12,1.35e-01,JUN
244,Facilitative sodium-independent glucose transporters,1/12,1.35e-01,SLC2A1
245,Metabolism,13/1615,1.35e-01,EPHX2; DCK; AGMAT; LDHB; NT5E; PNP; POLR1D; CMPK2; PHGDH; APOE; ANGPTL4; LDLRAP1; LDLR
246,Organic cation/anion/zwitterion transport,1/13,1.41e-01,SLC22A4
247,MAP kinase downregulation by phosphorylation of MEK1 by Cdk5/p35,1/13,1.41e-01,EGR1
248,Interleukin-22 soluble receptor signaling pathway,1/13,1.41e-01,JAK3
249,Ghrelin-mediated regulation of food intake and energy homeostasis,1/13,1.41e-01,IGFBP3
250,TACI and BCMA stimulation of B cell immune responses,1/13,1.41e-01,MAPK14
251,Signal regulatory protein (SIRP) family interactions,1/13,1.41e-01,SIRPG
252,MAP kinase signaling pathway,2/81,1.41e-01,JUN; MAPK14
253,Response to elevated platelet cytosolic calcium,2/83,1.44e-01,SERPINE1; THBS1
254,T cell signal transduction,2/83,1.44e-01,MAPK14; PRKCZ
255,MAP kinase inactivation of SMRT corepressor,1/14,1.45e-01,MAPK14
256,Interferon gamma signaling regulation,1/14,1.45e-01,IFNG
257,DCC-mediated attractive signaling,1/14,1.45e-01,ABLIM1
258,T cell receptor/JNK pathway,1/14,1.45e-01,JUN
259,Polyamine metabolism,1/14,1.45e-01,AGMAT
260,Acetylcholine binding and downstream events,1/14,1.45e-01,CHRNA3
261,AKT phosphorylation of cytosolic targets,1/14,1.45e-01,CDKN1A
262,Small cell lung cancer,2/84,1.45e-01,CDKN2B; BIRC3
263,Adhesion and diapedesis of lymphocytes,1/14,1.45e-01,CXCL8
264,HDL-mediated lipid transport,1/15,1.51e-01,APOE
265,Interleukin-17 signaling pathway,1/15,1.51e-01,CXCL8
266,Hematopoiesis regulation by cytokines,1/15,1.51e-01,CXCL8
267,Calcium signaling by HBx of hepatitis B virus,1/15,1.51e-01,JUN
268,HIF-1 degradation in normoxia,2/88,1.51e-01,MAPK14; PRKCZ
269,"Androgen receptor signaling, proteolysis, and transcription regulation",2/88,1.51e-01,CDKN1A; JUN
270,Peptide G-protein coupled receptors,3/192,1.51e-01,CX3CR1; CXCL8; CCL3
271,Repression of pain sensation by the transcriptional regulator DREAM,1/15,1.51e-01,JUN
272,Thymic stromal lymphopoietin (TSLP) pathway,2/90,1.55e-01,CXCL8; CCL3
273,Cell cycle,5/453,1.55e-01,CDKN1A; CDKN2B; CDKN2A; MYBL2; NDEL1
274,Amino acid biosynthesis and interconversion (transamination),1/16,1.55e-01,PHGDH
275,Rb tumor suppressor/checkpoint signaling in response to DNA damage,1/16,1.55e-01,CDKN1A
276,SREBF and miR-33 in cholesterol and lipid homeostasis,1/16,1.55e-01,LDLR
277,TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),1/16,1.55e-01,PRKCZ
278,Hypoxia-inducible factor in the cardivascular system,1/16,1.55e-01,JUN
279,Interleukin-10 anti-inflammatory signaling pathway,1/16,1.55e-01,MAPK14
280,Interleukin-9 signaling pathway,1/16,1.55e-01,JAK3
281,Destabilization of mRNA by KSRP,1/17,1.56e-01,MAPK14
282,Dendritic cells in regulating TH1 and TH2 development,1/17,1.56e-01,IFNG
283,Inflammasomes,1/17,1.56e-01,AIM2
284,TAK1-mediated activation of p38 MAPK,1/17,1.56e-01,MAPK14
285,Integrin beta-5 pathway,1/17,1.56e-01,PLAU
286,NO2-dependent IL-12 pathway in NK cells,1/17,1.56e-01,IFNG
287,Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs),1/17,1.56e-01,IGFBP3
288,Syndecan 3 pathway,1/17,1.56e-01,CXCL8
289,Axon guidance,4/325,1.56e-01,ABLIM1; SIAH2; SIAH1; RHOC
290,Cadmium-induced DNA biosynthesis and proliferation in macrophages,1/17,1.56e-01,JUN
291,Signaling by ERBB4,2/93,1.56e-01,CDKN1A; HBEGF
292,Fc gamma receptor-mediated phagocytosis,2/94,1.56e-01,WASF1; FCGR1A
293,Cells and molecules involved in local acute inflammatory response,1/17,1.56e-01,CXCL8
294,Renin-angiotensin system,1/17,1.56e-01,MME
295,Platelet sensitization by LDL,1/17,1.56e-01,MAPK14
296,Atypical NF-kappaB pathway,1/17,1.56e-01,MAPK14
297,Adaptive immune system,6/606,1.58e-01,CDKN1A; UBE2L6; KIR2DL1; FCGR1A; KIR2DL3; KIR2DL4
298,"Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds",2/96,1.58e-01,SLC22A4; SLC2A1
299,Pre-NOTCH processing in Golgi,1/18,1.61e-01,FURIN
300,Serotonin receptor 4/6/7 and NR3C signaling,1/18,1.61e-01,EGR1
301,Effect of METS on macrophage differentiation,1/18,1.61e-01,JUN
302,Human cytomegalovirus and MAP kinase pathways,1/18,1.61e-01,MAPK14
303,Hypoxic and oxygen homeostasis regulation of HIF-1-alpha,1/19,1.65e-01,CDKN2A
304,G-protein-independent seven transmembrane receptor signaling,1/19,1.65e-01,MAPK14
305,Calcineurin in effects in keratinocyte differentiation,1/19,1.65e-01,CDKN1A
306,Lissencephaly gene (LIS1) in neuronal migration and development,1/19,1.65e-01,NDEL1
307,STAT3 pathway,1/19,1.65e-01,JAK3
308,Apoptosis modulation by HSP70,1/19,1.65e-01,HSPA1B
309,Antigen-activated B-cell receptor generation of second messengers,3/211,1.65e-01,JUN; MAPK14; PRKCZ
310,Signaling by NODAL,1/19,1.65e-01,FURIN
311,Signaling by ERBB2,2/102,1.68e-01,CDKN1A; HBEGF
312,GATA3-mediated activation of Th2 cytokine expression,1/20,1.71e-01,MAPK14
313,Interleukin-3 regulation of hematopoietic cells,1/20,1.71e-01,CXCL8
314,Nerve growth factor (NGF) pathway,1/20,1.71e-01,JUN
315,Interleukin-4 signaling pathway,2/104,1.71e-01,MAPK14; JAK3
316,Nicotine activity on dopaminergic neurons,1/21,1.76e-01,CHRNA3
317,Mitochondrial role in apoptotic signaling,1/21,1.76e-01,BIRC3
318,IGF1 signaling pathway,1/21,1.76e-01,JUN
319,Signaling by NGF,3/221,1.76e-01,CDKN1A; FURIN; MAPK14
320,Y branching of actin filaments,1/21,1.76e-01,WASF1
321,p38 MK2 pathway,1/21,1.76e-01,MAPK14
322,Epstein-Barr virus LMP1 signaling,1/22,1.83e-01,CXCL8
323,Leptin influence on immune response,2/110,1.83e-01,CX3CR1; IFNG
324,Mitochondrial pathway of apoptosis: antiapoptotic Bcl-2 family,1/23,1.86e-01,MAPK14
325,Modulation of interferon signaling by chaperones,1/23,1.86e-01,IFNG
326,Interleukin-11 pathway,1/23,1.86e-01,JUN
327,RNA polymerase III transcription termination,1/23,1.86e-01,POLR1D
328,Th1/Th2 differentiation pathway,1/23,1.86e-01,IFNG
329,CREB transcription factor and its extracellular signals,1/23,1.86e-01,MAPK14
330,Eicosanoid metabolism,1/23,1.86e-01,EPHX2
331,Inhibition of cellular proliferation by Gleevec,1/24,1.93e-01,JUN
332,CXCR4 signaling pathway,2/116,1.95e-01,RHOC; PRKCZ
333,G0 and early G1 pathway,1/25,1.95e-01,MYBL2
334,TPO signaling pathway,1/25,1.95e-01,JUN
335,Corticotropin releasing hormone pathway,1/25,1.95e-01,CXCL8
336,C-Myc pathway,1/25,1.95e-01,CDKN2A
337,Ghrelin pathway,1/25,1.95e-01,CXCL8
338,RNA polymerase I transcription initiation,1/25,1.95e-01,POLR1D
339,Alpha-9 beta-1 integrin pathway,1/25,1.95e-01,TGM2
340,Phosphoinositides and their downstream targets,1/25,1.95e-01,PRKCZ
341,SHC1 events in ERBB2 signaling,1/25,1.95e-01,HBEGF
342,Signaling by NOTCH,2/119,1.97e-01,JUN; FURIN
343,Disease,6/674,2.00e-01,LDHB; CDKN1A; CXCL8; IGFBP3; RPL22; MFGE8
344,Interleukin-27-mediated signaling events,1/26,2.00e-01,IFNG
345,Interleukin-9 regulation of target genes,1/26,2.00e-01,CCL3
346,Oxidative stress,1/27,2.03e-01,MAPK14
347,Insulin regulation of blood glucose,1/27,2.03e-01,PRKCZ
348,FSH signaling pathway,1/27,2.03e-01,MAPK14
349,Rho GTPase cycle,2/123,2.03e-01,ARAP2; RHOC
350,Cell cycle: G2/M checkpoint,1/27,2.03e-01,CDKN1A
351,RNA polymerase III transcription initiation from type 2 promoter,1/27,2.03e-01,POLR1D
352,eIF4E and p70 S6 kinase regulation,1/27,2.03e-01,MAPK14
353,PERK-regulated gene expression,1/28,2.06e-01,CXCL8
354,Neurotrophin signaling pathway,2/126,2.06e-01,JUN; MAPK14
355,Interleukin receptor SHC signaling,1/28,2.06e-01,JAK3
356,SLC-mediated transmembrane transport,3/251,2.06e-01,SLC22A4; SLC2A1; SLC16A10
357,RNA polymerase III transcription initiation From type 3 promoter,1/28,2.06e-01,POLR1D
358,TGF-beta receptor activation of SMADs,1/28,2.06e-01,FURIN
359,"PTM: gamma carboxylation, hypusine formation and arylsulfatase activation",1/28,2.06e-01,FURIN
360,Integrin beta-2 pathway,1/29,2.08e-01,PLAU
361,Influence of Ras and Rho proteins on G1 to S transition,1/29,2.08e-01,CDKN1A
362,IGF1 pathway,1/29,2.08e-01,PRKCZ
363,Skeletal myogenesis control by HDAC and calcium/calmodulin-dependent kinase (CaMK),1/29,2.08e-01,MAPK14
364,ADP-ribosylation factor,1/29,2.08e-01,ARAP2
365,Sema4D in semaphorin signaling,1/29,2.08e-01,RHOC
366,RNA polymerase,1/29,2.08e-01,POLR1D
367,CDO in myogenesis,1/29,2.08e-01,MAPK14
368,Cell-cell communication,2/129,2.08e-01,SIRPG; MAPK14
369,PDGFB signaling pathway,2/129,2.08e-01,JUN; PPP2R2B
370,Ovarian infertility genes,1/30,2.08e-01,EGR1
371,MicroRNAs in muscle cell differentiation,1/30,2.08e-01,PRKCZ
372,Interleukin-2/STAT5 pathway,1/30,2.08e-01,JAK3
373,Interferon-beta enhancer pathway,1/30,2.08e-01,JUN
374,PDGFA signaling pathway,1/30,2.08e-01,JUN
375,Signaling pathway from G-protein families,1/30,2.08e-01,JUN
376,Retinoic acid receptor-mediated signaling,1/30,2.08e-01,MAPK14
377,Activation of matrix metalloproteinases,1/30,2.08e-01,FURIN
378,p38-alpha and p38-beta regulation,1/30,2.08e-01,MAPK14
379,Signal amplification,1/31,2.12e-01,MAPK14
380,Amino acid transport across the plasma membrane,1/31,2.12e-01,SLC16A10
381,Ras family activation regulation,1/31,2.12e-01,PRKCZ
382,Tight junction,2/133,2.12e-01,PPP2R2B; PRKCZ
383,Adipogenesis,2/133,2.12e-01,CDKN1A; SERPINE1
384,Alpha-6 beta-4 integrin signaling pathway,1/31,2.12e-01,MAPK14
385,NGF signaling via TRKA from the plasma membrane,2/136,2.16e-01,CDKN1A; MAPK14
386,Serotonin HTR1 group and FOS pathway,1/32,2.16e-01,MAPK14
387,Syndecan 4 pathway,1/32,2.16e-01,THBS1
388,"Glycine, serine and threonine metabolism",1/32,2.16e-01,PHGDH
389,Adrenergic pathway,2/137,2.17e-01,MAPK14; PRKCZ
390,Diabetes pathways,2/137,2.17e-01,CXCL8; IGFBP3
391,Negative regulators of RIG-I/MDA5 signaling,1/33,2.18e-01,UBE2L6
392,Glycoprotein VI-mediated activation cascade,1/33,2.18e-01,PRKCZ
393,Syndecan 2 pathway,1/33,2.18e-01,CXCL8
394,Propanoate metabolism,1/33,2.18e-01,LDHB
395,Systemic lupus erythematosus,2/139,2.19e-01,IFNG; FCGR1A
396,Monoamine transport,1/34,2.21e-01,MAPK14
397,Induction of apoptosis through DR3 and DR4/5 death receptors,1/34,2.21e-01,BIRC3
398,EPO receptor signaling,1/34,2.21e-01,JUN
399,Cysteine and methionine metabolism,1/34,2.21e-01,LDHB
400,TOR signaling,1/34,2.21e-01,PRR5L
401,EGF receptor transactivation by GPCRs in cardiac hypertrophy,1/34,2.21e-01,JUN
402,Primary immunodeficiency,1/35,2.23e-01,JAK3
403,Prion diseases,1/35,2.23e-01,EGR1
404,Arf6 signal transduction regulation,1/35,2.23e-01,ARAP2
405,fMLP induced chemokine gene expression in HMC-1 cells,1/35,2.23e-01,MAPK14
406,Interleukin-7 signaling pathway,1/35,2.23e-01,JAK3
407,PIK3C1/AKT pathway,1/35,2.23e-01,CDKN1A
408,Glycogen metabolism,1/36,2.27e-01,PPP2R2B
409,PI3K/PLC/TRK pathway,1/36,2.27e-01,EGR1
410,Signaling to ERKs,1/36,2.27e-01,MAPK14
411,PI3K/AKT activation,1/37,2.31e-01,CDKN1A
412,ALK in cardiac myocytes,1/37,2.31e-01,TGFBR3
413,Allograft rejection,1/37,2.31e-01,IFNG
414,BMAL1-CLOCK/NPAS2 activates circadian expression,1/38,2.35e-01,SERPINE1
415,Signaling of hepatocyte growth factor receptor,1/38,2.35e-01,JUN
416,ERBB4 signaling events,1/38,2.35e-01,HBEGF
417,GAB1 signalosome,1/39,2.39e-01,CDKN1A
418,FAS pathway and stress induction of heat shock protein regulation,1/39,2.39e-01,JUN
419,Signaling events regulated by Ret tyrosine kinase,1/39,2.39e-01,JUN
420,Phagosome,2/154,2.42e-01,FCGR1A; THBS1
421,Pyruvate metabolism and citric acid (TCA) cycle,1/40,2.42e-01,LDHB
422,Nuclear signaling by ErbB4,1/40,2.42e-01,HBEGF
423,PAC1 receptor pathway,1/40,2.42e-01,PRKCZ
424,Plasma membrane estrogen receptor signaling,1/41,2.46e-01,HBEGF
425,Bioactive peptide-induced signaling pathway,1/41,2.46e-01,MAPK14
426,Fc epsilon receptor I signaling in mast cells,1/41,2.46e-01,JUN
427,Hexose transport,1/42,2.50e-01,SLC2A1
428,Signaling events mediated by T cell protein tyrosine phosphatase (TC-PTP),1/42,2.50e-01,JAK3
429,Eukaryotic transcription initiation,1/42,2.50e-01,POLR1D
430,Type 1 diabetes mellitus,1/43,2.53e-01,IFNG
431,Voltage-gated potassium channels,1/43,2.53e-01,KCNH7
432,Mitotic prometaphase,1/43,2.53e-01,NDEL1
433,PI3K class IB pathway in neutrophils,1/43,2.53e-01,PRKCZ
434,ERBB2/ERBB3 signaling events,1/44,2.57e-01,JUN
435,HNF3A pathway,1/44,2.57e-01,JUN
436,RNA polymerase III transcription,1/45,2.60e-01,POLR1D
437,Integrin-linked kinase signaling,1/45,2.60e-01,JUN
438,"Interleukin-3, interleukin-5, and GM-CSF signaling",1/45,2.60e-01,JAK3
439,Alzheimer's disease,2/169,2.66e-01,MME; APOE
440,Agrin in postsynaptic differentiation,1/47,2.69e-01,JUN
441,Presenilin action in Notch and Wnt signaling,1/48,2.73e-01,JUN
442,Energy metabolism,1/48,2.73e-01,MAPK14
443,Interleukin-5 signaling pathway,1/49,2.77e-01,JUN
444,Amino acid and oligopeptide SLC transporters,1/49,2.77e-01,SLC16A10
445,Type 2 diabetes mellitus,1/50,2.81e-01,PRKCZ
446,Amyloids,1/51,2.85e-01,MFGE8
447,Metabolism of vitamins and cofactors,1/51,2.85e-01,SLC2A1
448,Lipid and lipoprotein metabolism,4/489,2.88e-01,APOE; ANGPTL4; LDLRAP1; LDLR
449,Pyruvate metabolism,1/52,2.88e-01,LDHB
450,Interleukin-2 receptor beta chain in T cell activation,1/52,2.88e-01,JAK3
451,JNK/MAPK pathway,1/53,2.91e-01,JUN
452,Amyotrophic lateral sclerosis (ALS),1/53,2.91e-01,MAPK14
453,Arginine and proline metabolism,1/54,2.94e-01,AGMAT
454,Kit receptor signaling pathway,1/54,2.94e-01,MAPK14
455,Non-small cell lung cancer,1/54,2.94e-01,CDKN2A
456,RNA polymerase I transcription,1/55,2.98e-01,POLR1D
457,Acute myeloid leukemia,1/57,3.05e-01,FLT3
458,Mechanism of gene regulation by peroxisome proliferators via PPAR-alpha,1/57,3.05e-01,JUN
459,Pathogenic Escherichia coli infection,1/57,3.05e-01,TLR5
460,PI3K cascade,1/57,3.05e-01,CDKN1A
461,HIV-1 Nef as negative effector of Fas and TNF,1/58,3.08e-01,BIRC3
462,Arachidonic acid metabolism,1/58,3.08e-01,EPHX2
463,Amino acid metabolism,2/195,3.11e-01,PHGDH; AGMAT
464,Caspase cascade in apoptosis,1/59,3.12e-01,BIRC3
465,Natural killer cell receptor signaling pathway,1/60,3.15e-01,MAPK14
466,Neurotrophic factor-mediated Trk receptor signaling,1/60,3.15e-01,PRKCZ
467,Androgen receptor proteolysis and transcription regulation,1/61,3.18e-01,CDKN2A
468,Leptin signaling pathway,1/61,3.18e-01,MAPK14
469,Signaling events mediated by focal adhesion kinase,1/62,3.20e-01,JUN
470,Circadian rhythm,1/62,3.20e-01,SERPINE1
471,Colorectal cancer,1/62,3.20e-01,JUN
472,Proteasome degradation,1/63,3.24e-01,IFNG
473,Validated nuclear estrogen receptor alpha network,1/64,3.26e-01,JUN
474,Interferon alpha/beta signaling,1/64,3.26e-01,EGR1
475,MAPK cascade role in angiogenesis,1/64,3.26e-01,MAPK14
476,DNA replication,2/207,3.28e-01,CDKN1A; NDEL1
477,Endochondral ossification,1/66,3.32e-01,PLAU
478,Semaphorin interactions,1/66,3.32e-01,RHOC
479,Destabilization of mRNA by AUF1 (hnRNP D0),1/66,3.32e-01,FCGR1A
480,Adipocytokine signaling pathway,1/67,3.34e-01,SLC2A1
481,SIDS susceptibility pathways,1/67,3.34e-01,CXCL8
482,G alpha 13 pathway,1/67,3.34e-01,PRKCZ
483,AMPK signaling,1/68,3.38e-01,CDKN1A
484,PPAR signaling pathway,1/69,3.41e-01,ANGPTL4
485,Pancreatic cancer,1/70,3.43e-01,CDKN2A
486,Signaling events mediated by VEGFR1 and VEGFR2,1/70,3.43e-01,MAPK14
487,G alpha q pathway,1/70,3.43e-01,PRKCZ
488,MicroRNA regulation of DNA damage response,1/70,3.43e-01,CDKN1A
489,Bacterial invasion of epithelial cells,1/71,3.46e-01,WASF1
490,Cyclin A-Cdk2-associated events at S phase entry,1/72,3.49e-01,CDKN1A
491,Myocyte adrenergic pathway,1/72,3.49e-01,MAPK14
492,Cap-dependent translation initiation,1/73,3.52e-01,RPL22
493,Wnt/calcium/cyclic GMP pathway,1/74,3.54e-01,PRKCZ
494,Integrins in angiogenesis,1/74,3.54e-01,MFGE8
495,Adherens junction cell adhesion,1/74,3.54e-01,WASF1
496,VEGF signaling pathway,1/76,3.60e-01,MAPK14
497,RIG-I/MDA5-mediated induction of interferon-alpha/beta pathways,1/76,3.60e-01,UBE2L6
498,Transcriptional regulation of white adipocyte differentiation,1/77,3.62e-01,ANGPTL4
499,G alpha (12/13) signaling events,1/77,3.62e-01,RHOC
500,Peroxisome,1/78,3.65e-01,EPHX2
501,Signaling by SCF-KIT,1/78,3.65e-01,CDKN1A
502,Antigen processing: cross presentation,1/79,3.66e-01,FCGR1A
503,Unfolded protein response,1/79,3.66e-01,CXCL8
504,Fc epsilon receptor I signaling pathway,1/79,3.66e-01,MAPK14
505,GPCR ligand binding,3/410,3.76e-01,CX3CR1; CXCL8; CCL3
506,Platelet homeostasis,1/82,3.76e-01,MAPK14
507,ECM-receptor interaction,1/84,3.83e-01,THBS1
508,Integrin cell surface interactions,1/85,3.84e-01,THBS1
509,MicroRNAs in cardiomyocyte hypertrophy,1/85,3.84e-01,MAPK14
510,Myc active pathway,1/85,3.84e-01,SLC2A1
511,mRNA stability regulation by proteins that bind AU-rich elements,1/86,3.86e-01,MAPK14
512,"Non-class A, B, C GPCRs",1/86,3.86e-01,CELSR2
513,Progesterone-mediated oocyte maturation,1/86,3.86e-01,MAPK14
514,DNA replication pre-Initiation,1/88,3.92e-01,CDKN1A
515,Prostate cancer,1/89,3.95e-01,CDKN1A
516,"Antigen presentation: folding, assembly, and peptide loading of class I MHC proteins",2/255,3.99e-01,UBE2L6; FCGR1A
517,Transmembrane transport of small molecules,3/432,4.00e-01,SLC22A4; SLC2A1; SLC16A10
518,Extracellular matrix organization,1/93,4.06e-01,FURIN
519,Cell surface interactions at the vascular wall,1/94,4.09e-01,SIRPG
520,Transport of inorganic cations/anions and amino acids/oligopeptides,1/95,4.10e-01,SLC16A10
521,"RNA polymerase I, RNA polymerase III, and mitochondrial transcription",1/95,4.10e-01,POLR1D
522,G-protein signaling pathways,1/95,4.10e-01,PRKCZ
523,M phase pathway,1/96,4.13e-01,NDEL1
524,Downstream signaling events Of B cell receptor (BCR),1/98,4.19e-01,CDKN1A
525,Potassium channels,1/99,4.20e-01,KCNH7
526,Granule cell survival pathway,1/99,4.20e-01,JUN
527,Neuronal system,2/283,4.44e-01,CHRNA3; KCNH7
528,Cytoplasmic ribosomal proteins,1/108,4.47e-01,RPL22
529,Signaling by interleukins,1/109,4.50e-01,JAK3
530,Signaling by EGFR in cancer,1/111,4.55e-01,CDKN1A
531,S phase,1/112,4.56e-01,CDKN1A
532,Lipid metabolism regulation by peroxisome proliferator-activated receptor alpha (PPAR-alpha),1/112,4.56e-01,ANGPTL4
533,Cell cycle checkpoints,1/117,4.69e-01,CDKN1A
534,Tricarboxylic acid (TCA) cycle and respiratory electron transport,1/117,4.69e-01,LDHB
535,Leukocyte transendothelial migration,1/117,4.69e-01,MAPK14
536,G alpha s pathway,1/120,4.77e-01,MAPK14
537,Influenza viral RNA transcription and replication,1/125,4.89e-01,RPL22
538,Integration of energy metabolism,1/125,4.89e-01,SLC2A1
539,Spliceosome,1/127,4.94e-01,HSPA1B
540,Signaling by FGFR in disease,1/128,4.96e-01,CDKN1A
541,Parkinson's disease,1/131,5.03e-01,UBE2L6
542,Influenza infection,1/142,5.31e-01,RPL22
543,Calcium regulation in the cardiac cell,1/149,5.48e-01,PRKCZ
544,Signaling by the B cell receptor (BCR),1/151,5.51e-01,CDKN1A
545,Translation,1/151,5.51e-01,RPL22
546,Gene expression,5/968,5.52e-01,CDKN2B; SERPINE1; RPL22; POLR1D; MAPK14
547,Integrated breast cancer pathway,1/152,5.52e-01,JUN
548,Signaling by GPCR,5/977,5.59e-01,CX3CR1; CXCL8; CCL3; RHOC; HBEGF
549,Generic transcription pathway,2/377,5.80e-01,CDKN2B; SERPINE1
550,Protein processing in the endoplasmic reticulum,1/166,5.81e-01,HSPA1B
551,"Fatty acid, triacylglycerol, and ketone body metabolism",1/173,5.95e-01,ANGPTL4
552,Metapathway biotransformation,1/174,5.96e-01,EPHX2
553,Transcription,1/181,6.10e-01,POLR1D
554,Huntington's disease,1/184,6.15e-01,TGM2
555,Transmission across chemical synapses,1/190,6.26e-01,CHRNA3
556,Post-translational protein modification,1/196,6.36e-01,FURIN
557,G alpha (i) signaling events,1/199,6.41e-01,CXCL8
558,Messenger RNA processing,1/203,6.47e-01,CLK1
559,Gastrin-CREB signaling pathway via PKC and MAPK,1/206,6.52e-01,HBEGF
560,Protein metabolism,2/442,6.57e-01,RPL22; FURIN
561,Actin cytoskeleton regulation,1/226,6.84e-01,WASF1
562,Carbohydrate metabolism,1/235,6.97e-01,SLC2A1
563,Class A GPCRs (rhodopsin-like),1/253,7.22e-01,CX3CR1
564,Neuroactive ligand-receptor interaction,1/272,7.47e-01,CHRNA3
